Abstract Several important studies were presented at the 2015 ASCO Annual Meeting in the field of breast cancer. Austrian Breast and Colorectal Study Group trial 18 again indicated the importance of bone health in postmenopausal women receiving endocrine therapy and showed that denosumab, a monoclonal antibody targeting the RANK ligand, was highly active in the reduction of fracture rates in this population. In the metastatic setting, addition of palbociclib to fulvestrant nearly tripled progression-free survival in pretreated women with luminal breast cancer as shown in the randomized phase III PALOMA-3 trial. In HER2-positive breast cancer, results from a randomized phase II study suggested that T-DM1 with or without endocrine therapy may be a valuable option as neoadjuvant treatment. In this trial, pathologic complete remission rates of > 40 % were observed after only four cycles of T-DM1. The phase III ExteNET study evaluated the role of neratinib, a tyrosine-kinase inhibitor targeting HER2 and epidermal growth factor receptor, as extended adjuvant therapy after 1 year of trastuzumab; while the future role of neratinib remains still undefined, this was the first study to show an improvement in terms of disease-free survival over the current treatment standard. Finally, the MARIANNE trial showed that T-DM1 was as effective as trastuzumab plus docetaxel as firstline therapy, while dual HER2-inhibition with T-DM1 plus pertuzumab yielded no further benefit.
Bone health is regarded as a major issue in postmenopausal women receiving antihormonal therapy for early stage breast cancer. Bisphosphonates were shown to prevent bone-mineral density loss [1] and apparently convey a survival benefit as well when given as adjuvant treatment [2] yet no significant reduction in the rate of fractures was reported. At this year's ASCO Annual Meeting, first results of Austrian Breast and Colorectal Study Group (ABCSG) trial 18 were reported [3] ; this prospective, double-blind, placebo-controlled phase 3 trial investigated the activity of denosumab, a fully human monoclonal antibody targeting the RANK-ligand, in the prevention of cancer-treatment induced bone loss in postmenopausal hormone-receptor (HR) positive breast cancer patients on aromatase-inhibitor therapy.
A total number of 3420 patients from 58 Austrian centers were randomly assigned to receive denosumab or placebo subcutaneously once every 6 months; time from randomization to first clinical fracture was defined as primary study endpoint.
Overall, the number of fractures was shown to be significantly lower in the denosumab as compared with the placebo group independent of baseline bone mineral density t-scores (92 vs. 172; HR 0.44; 95 % confidence interval (CI) 0.31-0.64; p < 0.001); time to first clinical fracture was significantly delayed in the denosumab group as well (HR 0.50; p < 0.001). Of note, the incidence of adverse or serious adverse events did not differ 1 3 between both treatment groups; in addition, no case of osteonecrosis of the jaw was reported.
Therefore, denosumab was shown to be a highly active bone-protective agent in this setting. Of note, the lacking correlation of fracture rates and baseline bone-mineral density clearly indicates that conventional bone-density scans may not be an optimal tool for the assessment of fracture risk; furthermore, the high rate of fractures in the overall population indicates that bone health is of foremost importance in this patient group. To fully understand the potential role of denosumab in early breast cancer, data regarding recurrence rates are eagerly awaited.
Palbocolib plus fulvestrant in metastatic luminal breast cancer
Dysregulation of cell-cycle control is a hallmark of malignant disease and anticancer activity of cyclin-dependent kinase (CDK) 4 and 6 inhibitors has already been demonstrated in preclinical models and early stage clinical trials. In the randomized phase II PALOMA-1 trial, addition of the CDK 4/6 inhibitor palbociclib to letrozole prolonged progression-free survival (PFS) from 10.2 to 20.2 months (HR 0.488; 95 % CI 0.32-0.75; p = 0.0004) in the first-line setting [4] . At this year's ASCO Annual Meeting, results from PALOMA-3, a prospective randomized phase III trial of fulvestrant with or without palbociclib in pretreated patients with HR-positive metastatic breast cancer (MBC) were presented [5] .
A total number of 521 patients were included (347 fulvestrant plus palbocilib; 174 fulvestrant plus placebo); all patients had relapsed or progressed on prior endocrine therapy and one third had received prior chemotherapy as well. In this heavily pretreated population, fulvestrant yielded a PFS of 3.8 months, as compared with 9.2 months in the fulvestrant plus palbociclib cohort (HR 0.422; 95 % CI 0.32-0.56; p = <0.000001) indicating the ability of CDK 4/6 inhibitors to reverse resistance to endocrine therapy. Of note, consistent benefit from palbociclib was seen in pre and postmenopausal women alike. To little surprise, the most common side effects were leucopenia and neutropenia but febrile neutropenia rates were low and similar in both groups. Therefore, PALOMA-3 is another trial suggesting that CDK4/6 inhibitors are evolving to become a valuable novel treatment option in metastatic luminal breast cancer.
Adjuvant and neoadjuvant therapy of HER2-positve breast cancer
Dual HER2-inhibition is by now well-established in the metastatic setting as well as in the neoadjuvant treatment of early stage breast cancer. In the NeoSphere study, Gianni et al. investigated the impact of pertuzumab, trastuzumab or both antibodies when combined with chemotherapy as neoadjuvant therapy on pathologic complete response (pCR) rates; patients in a fourth arm received both antibodies without chemotherapy backbone [6] . Authors of this study had already reported a pCR rate as high as 45.8 % with dual HER2-inhibition plus docetaxel (PTD). As pCR correlates with superior survival outcome in high-risk breast cancer subtypes [7] , Gianni et al. now conducted a PFS analysis of NeoSphere at 5 years follow-up [8] .
A nonsignificant trend towards superior PFS outcomes was observed in the overall group of patients with pCR, which was somewhat more pronounced in the aggressive HR-negative subgroup (DFS 85 % vs. 72 %; HR 0.65; 95 % CI 0.32-1.30). A similar (nonsignificant) DFS benefit was seen in favor of PTD versus trastuzumab plus docetaxel (HR 0.69; 95 % CI 0.34-1.40). Of note, all patients received FEC as postoperative chemotherapy, thereby potentially "diluting" the effect of pCR. The phase II design may also reduce the chance for identifying a significant DFS benefit. Despite these issues, NeoSphere is of great relevance as these results have helped in defining dual HER2 blockade as the novel standard of care in the neoadjuvant treatment of HER2-positive breast cancer.
Another promising neoadjuvant therapy option was presented by the West German Study Group (WSG). Harbeck et al. presented data of an interim analysis of the HER2-positive/luminal B group of the ADAPT study [9] . In this phase II trial, 130 patients received trastuzumab plus endocrine therapy, T-DM1, or the combination of T-DM1 plus endocrine therapy for a total duration of 12 weeks. Similarly to NeoSphere, standard postoperative chemotherapy was recommended. pCR rates in breast and axilla were significantly higher in the T-DM1 containing arms-45.8 % (T-DM1 plus endocrine therapy) and 40.5 % (T-DM1 alone), respectively, as compared with 6.7 % in patients receiving trastuzumab plus endocrine treatment (p < 0.001). Despite the small sample size, these striking results clearly warrant further investigation of this treatment approach while a chemotherapy-free combination of trastuzumab plus endocrine treatment should not be recommended.
Finally, the randomized, placebo-controlled, phase III study ExteNET asked the question if 1 year of adjuvant treatment with the second-generation HER2 tyrosine-kinase inhibitor (TKI) neratinib after completion of standard therapy (including adjuvant trastuzumab) may result in a further reduction of recurrence events [10] . In this context, it is worthwhile remembering that the ALTTO trial (in which a sequential therapy of trastuzumab and lapatinib-albeit after 12 weeks of trastuzumab for a total duration of 1 year-was tested) yielded negative results [11] . Also, extension of adjuvant trastuzumab from 1 to 2 years was proven unsuccessful henceforth [12] .
A total number of 2480 patients (> 75 % node-positive) were randomized to receive neratinib 240 mg once per day continuously for 1 year or placebo. In this high-risk subset, extended adjuvant TKI therapy improved diseasefree survival rates at 2 years in the ITT population from 91.6 to 93.9 % (HR 0,67; 95 % CI 0,50-0,91; p = 0.009) albeit at the price of increased toxicity with 39.9 % of patients
Summary
In summary, several highly relevant studies reported results at the 2015 ASCO Annual Meeting and these data will eventually help in optimizing current treatment strategies.
Take-home massage ABCSG-18 observed a high rate of fractures in postmenopausal women receiving aromatase-inhibitors as adjuvant therapy; this rate was significantly reduced by denosumab. Palbociclib plus fulvestrant was vastly superior to fulvestrant alone in pretreated HR-positive MBC patients. T-DM1 was shown to be of promise as neoadjuvant therapy in the HER2-positive cohort of the ADAPT study, while the phase III ExteNET study could show that extended adjuvant treatment with neratinib after the conclusion of adjuvant trastuzumab therapy was superior to no further treatment. Finally, the MARIANNE trial confirmed that T-DM1 was as effective as docetaxel plus trastuzumab as first-line therapy but no further improvement with the addition of pertuzumab to T-DM1 was possible.
experiencing grade 3/4 diarrhea. Somewhat surprisingly, the DFS difference was exclusively driven by the HR-positive cohort (HR 0.51; 95 % CI 0.33-0.77; p = 0.001) with no additional benefit observed in HR-negative patients (HR 0.93; 95 % CI 0.6-1.43; p = 0.735), despite the latter usually considered as being at higher risk for recurrence. Doubts remain if neratinib may really become a novel treatment standard; beside toxicity issues, the research focus has currently switched from TKIs to dual HER2-inhibition and results of the APHINITY (NCT01358877) trial of trastuzumab plus pertuzumab as adjuvant therapy must be awaited in order to fully understand the optimal treatment strategy. Still, ExteNET is important in its own right as this was the first study to show a DFS improvement over the established treatment standard of 1 year adjuvant trastuzumab.
News in HER2-positive metastatic breast cancer
At the 2015 ASCO Annual Meeting, long-awaited results of the phase III MARIANNE trial were finally reported [13] . A total number of 1095 HER2-positive MBC patients without prior chemotherapy for metastatic disease were randomized to receive trastuzumab plus docetaxel, T-DM1 or a combination of T-DM1 and pertuzumab. Therefore, this study compared the former treatment standard of docetaxel plus trastuzumab (now already replaced by the combination of docetaxel, trastuzumab, and pertuzumab based upon the results of the CELOPA-TRA trial [14] ) to T-DM1 or dual HER2-blockade with T-DM1 plus pertuzumab. Results of a phase II trial had already suggested that activity of T-DM1 may be similar to trastuzumab plus docetaxel in the first-line setting [15] and the TH3RESA trial indicated that T-DM1 was superior to trastuzumab plus chemotherapy in heavily pretreated patients [16] .
Results of this trial indicated no significant difference in terms of PFS (trastuzumab plus docetaxel 13.7 vs. 14.1 months on T-DM1 (HR 0.91; 0.73-1.13) and 15.2 months (HR 0.87; 95 % CI 0.69-1.08) on T-DM1 plus pertuzumab, respectively) and response rates in between the three treatment groups while duration of response clearly favored the T-DM1 containing arms. Therefore, docetaxel combined with trastuzumab plus pertuzumab remains the golden standard of first-line therapy. Still, based upon the outcome data from MARIANNE and EMILIA [17] , T-DM1 appears to be an alternative firstline option in patients with early progression on or after adjuvant trastuzumab or in patients not fit for standard treatment. The exact reason why dual HER2-inhibition with T-DM1 plus pertuzumab was not superior to T-DM1 alone is currently unknown and at first glance these data contradict results from the CLEOPATRA trial. One may speculate, however, that the unique mechanism of action of T-DM1 may not require inhibition of HER2/HER3 hetero-dimerization.
